<DOC>
	<DOCNO>NCT01692925</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate pharmacokinetics ( exposure trial drug body ) four lot turoctocog alfa ( human recombinant coagulation factor VIII ( FVIII ) ) subject haemophilia A .</brief_summary>
	<brief_title>Investigation Pharmacokinetics Turoctocog Alfa Subjects With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male subject diagnosis severe haemophilia A ( FVIII &lt; 1 % ) age 18 year Documented history least 150 exposure day FVIII product ( prevention treatment bleeds ) Immunocompetent ( HIV ( Human Immunodeficiency Virus ) positive subject CD4+ ( Cluster differentiation 4 ; glycoprotein express surface ) lymphocyte count &gt; 200/microL ) Detectable inhibitor FVIII ( equal 0.6 Bethesda Units ( BU ) ) History FVIII inhibitor Severe current hepatic dysfunction severe hepatic disease last 12 month Known suspect allergy trial product ( FVIII ) relate product Subjects receive immune modulate medication immune tolerance induction ( ITI ) regimens Body mass index ( BMI ) 30 kg/m^2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>